SCHEMBL2347895

SCHEMBL2347895

COC(=O)CCc1ccc(OC2c3cc(OC)ccc3CC2(C)C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 0.42
MAPT P10636 2/20 0.40
ALDH1A1 P00352 2/20 0.40
TDP1 Q9NUW8 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
KDM4E B2RXH2 1/20 0.39
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAOA P21397 1/20 0.39
SLC6A2 P23975 1/20 0.39
RAB9A P51151 1/20 0.39
SLC6A3 Q01959 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
EPHX2 P34913 1/20 0.39
VDR P11473 1/20 0.39
PPARD Q03181 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2351071 0.90 LMNA (0.38) F2RL1MAPTALDH1A1TDP1MEN1
SCHEMBL2351032 0.90 FFAR1 (0.47) F2RL1MAPTKDM4ENPC1LMNA
SCHEMBL2347885 0.89 EPHX2 (0.38) F2RL1MAPTALDH1A1KMT2ALMNA
SCHEMBL1744972 0.88 EPHX2 (0.39) F2RL1MAPTALDH1A1NPC1LMNA
SCHEMBL1744984 0.80 MTNR1A (0.50) MTNR1A
SCHEMBL2353768 0.79 PPARG (0.44) LMNACYP3A4
SCHEMBL2354270 0.78 FFAR1 (0.48) LMNACYP3A4
SCHEMBL19490670 0.77 SLC6A2 (0.43) MAOASLC6A2SLC6A3MTNR1A
SCHEMBL1745046 0.76 FFAR1 (0.48) LMNAEPHX2
SCHEMBL1747248 0.74 GRIN2B (0.44) F2RL1MAPTALDH1A1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 F2RL1 465/4885MAPT 4788/4885ALDH1A1 3163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.